Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab

BACKGROUND: Low‐density lipoprotein cholesterol (LDL‐C) is a risk factor for atherosclerotic cardiovascular disease (ASCVD). There are limited real‐world data on LDL‐C lowering with evolocumab in United States clinical practice. HYPOTHESIS: We assessed LDL‐C lowering during 1 year of evolocumab ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Nihar R., Wade, Rolin L., Xiang, Pin, Pinto, Lionel, Nunna, Sasikiran, Wang, Xin, Exter, Jason, Mues, Katherine E., Habib, Mohdhar, Chen, Chi‐Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119857/
https://www.ncbi.nlm.nih.gov/pubmed/33760276
http://dx.doi.org/10.1002/clc.23600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119857/
https://www.ncbi.nlm.nih.gov/pubmed/33760276
http://dx.doi.org/10.1002/clc.23600

Ejemplares similares